Lenalidomide and genetic profiling in myeloma, T-cell immunotherapy upregulates AML cell MHC-class II, and young fecal microbiota rejuvenate HSCs
Blood Podcast
00:00
The Effect of Lenalidomide Maintenance on Progression-Free Survival
The UK NCRI myeloma 11 Phase III trial included more than 1,400 patients. The study was based on the availability of baseline marrow for extended genetic profiling. Median overall survival was not reached with lenalidomide maintenance versus 70.8 months with observation.
Transcript
Play full episode
